Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 7/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | USP5 | P45974 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4427532 | 0.87 | USP5 (0.66) | HDAC1HDAC8SIGMAR1USP5HDAC6 | |
| SCHEMBL7740668 | 0.83 | HDAC6 (0.55) | HDAC1HDAC8HDAC6DRD2ALDH1A1 | |
| SCHEMBL5254053 | 0.79 | USP2 (0.64) | SIGMAR1ALDH1A1LMNAKMT2AMMP2 | |
| SCHEMBL3384299 | 0.77 | HDAC1 (1.00) | HDAC1HDAC8HDAC6 | |
| SCHEMBL15801111 | 0.76 | NPC1 (0.54) | SIGMAR1ALDH1A1LMNAKMT2AMMP2 | |
| Hydrochloric Acid SCHEMBL6132927 | 0.76 | USP2 (0.60) | SIGMAR1ALDH1A1LMNAGAAKMT2A | |
| SCHEMBL4434657 | 0.75 | MMP2 (0.56) | USP5MMP1LMNAGAAKMT2A | |
| SCHEMBL6134737 | 0.75 | USP2 (0.59) | SIGMAR1ALDH1A1LMNAKMT2AMMP2 | |
| SCHEMBL6413429 | 0.75 | RAD52 (0.47) | SIGMAR1USP5HDAC6DRD2ALDH1A1 | |
| SCHEMBL4659847 | 0.75 | SIGMAR1 (0.47) | HDAC1SIGMAR1USP5HDAC6DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0876343-B1 | AROMATIC KETO-ACIDS AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER LAMBERT CO (US) | 2002-03-13 | — | — | EP | claimed |
| US-6008220-A | A GELATINASE A INHIBITOR FOR TREATING MULTIPLE SCLEROSIS, ATHEROSCLEROTIC PLAQUE RUPTURE, AORTIC ANEURISM, HEART FAILURE, RESTENOSIS, PERIODONTAL DISEASE, CORNEAL ULCERATION, TREATMENT OF BURNS, DECUBITAL ULCERS, WOUND HEALING, CANCER | WARNER LAMBERT COMPANY (US) | 1999-12-28 | — | — | US | claimed |
| EP-0876343-A1 | AROMATIC KETO-ACIDS AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1998-11-11 | — | — | EP | claimed |
| WO-1997023459-A1 | AROMATIC KETO-ACIDS AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | claimed |
| US-8847003-B2 | Role of proteoglycans in drug dependence | SANNA PIETRO P (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140173764-A9 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | SANNA PIETRO P (US) | 2014-06-19 | — | — | US | disclosed |
| US-20120174240-A1 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | SANNA PIETRO P (US) | 2012-07-05 | — | — | US | disclosed |
| US-8119854-B2 | Role of proteoglycans in drug dependence | Sanna, Pietro P. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119854-B2 | Role of proteoglycans in drug dependence | Sanna, Pietro P. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100199361-A1 | Role of Proteoglycans in Drug Dependence | Sanna, Pietro Paolo (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100199361-A1 | Role of Proteoglycans in Drug Dependence | Sanna, Pietro Paolo (US) | 2010-08-05 | — | — | US | disclosed |
| US-20090186834-A1 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| EP-0946166-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999047138-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-09-23 | — | — | WO | disclosed |
| US-5948780-A | ADMINISTERING A METALLOPROTEINASE INHIBITOR | WARNER-LAMBERT COMPANY (US) | 1999-09-07 | — | — | US | disclosed |
| WO-1999032150-A1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| EP-0876343-A1 | AROMATIC KETO-ACIDS AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1998-11-11 | — | — | EP | disclosed |
| WO-1998026773-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |
| WO-1998025597-A2 | METHOD FOR TREATING AND PREVENTING HEART FAILURE AND VENTRICULAR DILATATION | WARNER-LAMBERT COMPANY (US) | 1998-06-18 | — | — | WO | disclosed |
| WO-1997023459-A1 | AROMATIC KETO-ACIDS AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140173764-A9 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | OGFR, CSGALNACT1, OPRL1 | HDAC1 192/4885HDAC8 472/4885SIGMAR1 140/4885 |
| US-20120174240-A1 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | OGFR, CSGALNACT1, OPRL1 | HDAC1 192/4885HDAC8 472/4885SIGMAR1 140/4885 |
| US-20100199361-A1 | Role of Proteoglycans in Drug Dependence | OGFR, CSGALNACT1, OPRL1 | HDAC1 192/4885HDAC8 472/4885SIGMAR1 140/4885 |
| US-20090186834-A1 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | NPC1L1, CYP46A1, NPC1 | HDAC1 837/4885HDAC8 2476/4885SIGMAR1 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.